| Title |
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan
|
|---|---|
| Published in |
Vascular Health and Risk Management, October 2013
|
| DOI | 10.2147/vhrm.s50831 |
| Pubmed ID | |
| Authors |
Nikos Maniadakis, Fotini Gialama |
| Abstract |
Hypertension represents a major health problem, affecting more than one billion adults worldwide. Irbesartan, an angiotensin II receptor blocker, is considered to be a highly effective treatment in the management of hypertension. The purpose of this review is to evaluate the efficacy, safety and tolerability profile, and cost-effectiveness of treatment with irbesartan in hypertension. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 54 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 19% |
| Researcher | 8 | 15% |
| Student > Ph. D. Student | 8 | 15% |
| Student > Bachelor | 5 | 9% |
| Professor | 2 | 4% |
| Other | 8 | 15% |
| Unknown | 13 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 15% |
| Economics, Econometrics and Finance | 4 | 7% |
| Nursing and Health Professions | 2 | 4% |
| Chemistry | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 17 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2013.
All research outputs
#15,281,593
of 22,725,280 outputs
Outputs from Vascular Health and Risk Management
#500
of 753 outputs
Outputs of similar age
#127,575
of 207,105 outputs
Outputs of similar age from Vascular Health and Risk Management
#15
of 19 outputs
Altmetric has tracked 22,725,280 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 753 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,105 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.